Astrazeneca Ab

Nektar Therapeutics

Targacept, Inc.

Tesfai Sebhatu

Martin Hans Bohlin

Stephan D Parent

David Thomas Jonaitis

Carl-Johan Aurell

Eric Thomas Healy

David Richard Jensen

Gary Maurice Dull

Craig Harrison Miller

Julio A Munoz

Peter Nordberg

Ursula Pettersson

Bengt Leonard Åslund

Bo Ingvar Ymén

Erica Tjerneld

Maria Lindkvist

Lars Lilljequist

Veronica Profir

Erica Ståhle

Caroline Ericsson

Bo Ingvar Ymen

Bengt Aslund

Stephan Parent

Bengt Leonard Aslund

Bo Ingvar YMÉN

Bengt Leonard ÅSlund

Naloxol-polyethylene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.

Crystalline naloxol-PEG conjugate

Naloxol-polyethlyene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.

Crystalline naloxol-peg conjugate

Phosphoric acid, edisylic acid (1,2-ethanedisulfonic acid), citric acid, orotic acid (uracil-6-carboxylic acid), R-mandelic acid, sulfuric acid, 1,5-naphthalenedisulfonic acid, D-aspartic acid, and lysine monohydrochloride salts of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine, and methods for their preparation, pharmaceutical compositions comprising said salts, and use, are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.

Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine

The salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing it and the use of it in therapy, and particularly in the therapy of GSK3 related conditions and disorders.

Citrate salt of an indole derivative and its pharmaceutical use

The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6 -dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt and to mixture thereof. Further, the present invention also relates to processes for obtaining them, the use of said compounds for the treatment of gastrointestinal disorders, and pharmaceutical compositions containing them.

Crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a] pyridine-6-carboxamide mesylate salt

Growing community of inventors

Sodertalje, Sweden

Tesfai Sebhatu